medigraphic.com

2001, Número S1

<< Anterior Siguiente >>

Arch Cardiol Mex 2001; 71 (S1)


Viabilidad miocárdica. Miocardio aturdido e hibernante. Utilidad de la centellografía miocárdica

Bialostozky D

Idioma: Español
Referencias bibliográficas: 36
Paginas: 25-31
Archivo PDF: 53.96 Kb.


RESUMEN

Gran importancia ha adquirido el diagnóstico de viabilidad en la miocardiopatía coronaria con insuficiencia cardiaca debido a los excelentes resultados terapéuticos obtenidos. Por su frecuencia, la identificación de viabilidad, ha adquirido proporciones de problema de salud pública. Se describen las características del miocardio aturdido e hibernante así como los protocolos que se utilizan para demostrar tanto la perfusión, reserva miocárdica y su actividad metabólica, con énfasis en los estudios que utilizan los radiotrazadores Talio-201 y Tc99m-sestamibi.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. HO KKI, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure, the Framingham study. J Am Coll Cardiol 1993; 22: 6A-13A.

  2. MARWICK TH: The viable myocardium- epidemiology, detection, and clinical implications. Lancet 1998; 351: 815-19.

  3. TILLISH J, BRUNKEN R, MARSHALL R, ET AL: Reveribilirty of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-88.

  4. BRUNKEN R, TILLIS J, SCHWAIGER M, ET AL: Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q wave infarctions: evidence of viable tissue in some infract regions by positron emission tomography. Circulation 1986; 173: 951-63.

  5. BRAUNWALD E, KIONER RA: The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982; 166: 1146-9.

  6. RAHIMTOOLA SH: A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985; 72(Suppl V): 123-135.

  7. BIALOSTOZKY D: Contribuciones de la medicina nuclear a los problemas de la cardiología. Arch Inst Cardiol Mex 1991; 61: 513-15.

  8. KLONER RA, BOFFL R, MARBAN E, ET AL: Medical and cellular implications of stunning, hybernation and preconditioning. A NHLBI workshop. Circulation 1998; 97: 1848-67.

  9. SCHWARZ ER, SCHOENDUBE FA, KOSTIN S, ET AL: Prolonged myocardial hibernation exacerbates cardiomyocytes degeneration and impaires recovery of function after revascularization. J Am Coll Cardiol 1998; 134: 1018-26.

  10. TOPOL EJ, WEISS JL, GUZMAN PA ET AL: Immediate improvement of dysfunctional myocardial segments after coronary revascularization: detection by intraoperative transesophageal echocardiography. J Am Coll Cardiol 1984; 4: 1123-34.

  11. BRAUNWALD E, RUTHERFORD JD: Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium”. J Am Coll Cardiol 1986; 8: 11467-70.

  12. PICCOLO E, DE MICHELI A, GARCIA PEREIRA D, COCCO F, SODI PALLARES D: L’évolution électrocardiographic des signes de nócrose au cours de I’infarctus du myocarde. Mal Cardiovasc 1960; 1(4): 503-34.

  13. MARGONATO A, CHIERCHIA SIL, XUEREB RG, ET AL: Specificity and sensitivity of exercise-indu-ced ST segment elevation for detection of residual viability: comparison with fluorodeoxyglucose and positron emission tomography. J Am Coll Cardiol 1995; 25: 11032-8.

  14. ROZANSKI A, BERMAN DS, GRAY R, ET AL: Use of thallium-102 redistribution scintigraphy in the preoperative differentiation of reversible and nonreversible myocardial asynergy. Circulation 1981; 64: 936-44.

  15. DILSIZIAN V: Myocardial Viability. A Clinical and Scientific Treatise. Futura Publishing Co Inc. Armonk NY 2000. Section 2, pg 461.

  16. BANKA VS, BODENHEIMER MM, HEFFANT RH: Determinants, of reversible asynergy. The native coronary circulation. Circulation 1975; 52: 810-16.

  17. DEWOOD MA, SPORES J, NOTSKE R, ET AL: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.

  18. DILSIZÁN V, ROCCO, TP, STRAUSS HW, ET AL: Technetium-99m isonitrile myocardial uptake at rest. 1: relation to severity of coronary stenosis. J Am Coll Cardiol 1989; 14: 3112-118 (1673-77).

  19. BIALOSTOZKY D: El Miocardio Aturdido e Hibernante. Importancia de la Cardiología Nuclear en su Detección. Diagnóstico de la Cardiopatía Isquémica. Un Enfoque Multidisciplinado. Editor Jesús Vargas Barrón. Editorial Médica Panamericana. México DF. 1999. pgs. 204-12.

  20. BIALOSTOZKY D, LECHUGA A, ALEXANDERSON E, ET AL: Viabilidad miocárdica. Arch Inst Cardiol Mex 1995; 65: 293-99.

  21. DILSIZIAN V, BONOW RO: Current diagnostic techniques of assessing myocardial viability in patients with hybernating and stunned myocardium. Circulation 1993; 187: 1-20.

  22. POHOST GM: Cardiovascular applications of magnetic resonance. Mount Kisco NY. American Heart Association. Futura Publishing Company. 1st Ed. 1993.

  23. KELLY MJ: Fluorina 18-labeled fluorodeoxyglucose myocardial scintigraphy with Anger gamma camera for assessing myocardial viability. J Nucl Cardiol 1995; 2: 360-5.

  24. TAMAKI N, KAWARNOTO M, TAKAHASHI N, ET AL: Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thahum imaging. J Am Coll Cardiol 1992; 22: 1621-7.

  25. WASHEK J, HINKLE G, BASMADJIAN G, ET AL: Effect of cardiac drugs on imaging studies with thallous chioride TI-201. Am J Hosp Pharm 1981; 38: 1726-8.

  26. DILSIZIAN V, ROCCO TP, FREEDMAN NM, ET AL: Enhanced detection of ischernic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Eng J Med 1990; 323: 141-45.

  27. DILSIZIAN V, ARRIGHI JA, CIODATI JG, ET AL: Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thakkium reinjection and [18F] Fluorodeoxyglucose. Circulation 1994; 189: 578-87.

  28. SAWADA SG, ALIMAN KC, MUZIK O, ET AL: Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994; 123: 92-8.

  29. UDDELSON JE, COLEMAN PS, METHERALL JA, ET AL: Predicting recovery of severe regional ventricular dysfunction- comparison of resting scintigraphy with201 TI and99mTc-sestamibi. Circulation 1994; 189: 2552-61.

  30. GERMANO G, KIAT H, KABANAGH PB, MORIEL M, MAZZANTI M, SU H-T, ET AL. Automatic qualification of ejection fraction from gated myocardial perfusion Spect. J Nucl Med 1995, 36: 2138-2147.

  31. BERMAN DA, KIAT H, FRIEDMAN JD, ET AL: Separate acquisition rest thallium-201 /stress Tc-99m sestamibi dual isotope myocardial perfusion single photon emission computer tomography (SPECT). J Nucl Cardiol 1994; 35: 81-8.

  32. BISL G, SCÍAGRA R, SANTORO GM, FAZZINI PF: Rest-Technetium-99m sestamibi in combination with short-term administration of nitrates, feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994; 124: 1282-9.

  33. SIAGRÁ R, BISI G, SANTORO GM, AGNOLUCCI M, ZOCCARATO O, FAZZINI PF: Influence of the assessment of defect severity and intravenous nitrate administration during tracer injection on the detection of viable hibernating myocardium with data-base quantitative technetium 99m-labeled sestamibi single-photon emission computed tomography. J Nucl Cardiol 1999; 3: 221-30.

  34. BATISTA JF, PEREZTOL O, VALDÉS JA, ET AL: Improved detection of myocardial perfusion reversibility by rest-nitroglycerine Tc 99mMBI: comparison with Tj1-201 reinjection. J Nucl Cardiol 1999; 6: 480-6.

  35. RAGOSTA M, BELLER GA,WATSON DD, ET AL: Quantitative planar rest-redistribution thallium imaging detection of myocardial viability and prediction of improvement in left vetricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87: 1630-41.

  36. SIEBELINK HMJ, BLANKSMA P, CRIJNS HJG, BAX JJ, ET AL: No difference in cardiac event-free survival between positron emission tomography- guided and single-photon emission computed tomography-guided patient management. J Am Coll Cardiol 2001; 137: 81-8.




2020     |     www.medigraphic.com